CSTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Castle Biosciences Inc (CSTL) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive analyst ratings and a strong corporate culture, its recent financial performance shows declining net income and EPS, which raises concerns about profitability. Additionally, there are no strong trading signals or significant catalysts to justify immediate action. A hold position is recommended until further clarity is provided by the upcoming Q1 2026 financial results.
The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a lack of strong upward trend. The stock is trading near its pivot level of 24.264, with resistance at 26.132 and support at 22.396.
Positive analyst ratings with increased price targets (e.g., Baird raised the target to $44).
Recognition as a top workplace, which reflects strong corporate culture and employee satisfaction.
Weak financial performance in Q4 2025, with a significant drop in net income (-124.32% YoY) and EPS (-125.81% YoY).
No significant hedge fund or insider trading trends.
No recent congress trading data or strong event-driven catalysts.
In Q4 2025, revenue increased slightly by 0.81% YoY to $87.01M. However, net income dropped significantly to -$2.33M (-124.32% YoY), and EPS fell to -$0.08 (-125.81% YoY). Gross margin improved slightly to 76.33% (+0.14% YoY), but profitability remains a concern.
Analysts are positive on CSTL, with multiple firms raising price targets recently (e.g., Baird to $44, KeyBanc to $50, Guggenheim to $47). The consensus rating is Outperform/Buy.
